We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Peroxisomes and disease
- Major metabolic pathways in peroxisomes
- Classification of peroxisomal disorders
- The Zellweger spectrum of PBDs
- PBDs are caused by mutations in peroxin (PEX) genes (1)
- PBDs are caused by mutations in peroxin (PEX) genes (2)
- Abnormalities in Zellweger syndrome: Diagnostic parameters
- Cellular consequences of impaired peroxisome function
- Single enzyme deficiencies: Adrenoleukodystrophy
- Development of therapies for treatment of peroxisomal disorders
- Thank You
- Financial disclosures
Topics Covered
- Major metabolic pathways in peroxisome
- Classification of peroxisomal disorders
- The Zellweger spectrum of peroxisome biogenesis disorders (PBDs)
- PBDs and mutations in PEX gene
- Development of therapies for treatment of peroxisomal disorders
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Schrader, M. (2026, May 28). Peroxisomal disorders [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 29, 2026, from https://doi.org/10.69645/NQQT6690.Export Citation (RIS)
Publication History
- Published on May 28, 2026
Financial Disclosures
- Prof. Michael Schrader has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome, everybody. My
name is Michael Schrader.
I'm a professor of
cell biology in
the Department of Biosciences
at the University of Exeter.
In my short talk, I would like
to address peroxisomal
disorders.
0:17
Peroxisomes were first
identified in 1954
by Johannes Rhodin through
electron microscopy.
They were characterised
biochemically by
Nobel laureate Christian
de Duve in the 1960s.
He revealed their
oxidative nature and role
in hydrogen peroxide
metabolism and named them
peroxisomes because
peroxisomes contain
several oxygen-consuming
oxidases,
which generate
hydrogen peroxide,
which can then be
degraded by catalase,
one of the most prominent
peroxisomal marker enzymes.
In 1973, Sidney Goldfischer
and colleagues discovered
that Zellweger syndrome
patients lack peroxisomes,
and this was the first
link to human disease.
Later on, the important role of
peroxisomes in the
breakdown of fatty acids,
for example, very long-chain
fatty acids, was discovered,
and very long-chain
fatty acids are also now
a specific biomarker for
peroxisomal disorders.
The first gene defect was
only identified in 1992.
1:39
What are the major metabolic
pathways of peroxisomes?
Peroxisomes possess
three ABCD transporters.
These are ABC transporters,
which are involved in the
uptake of a variety of
fatty acid substrates
into the peroxisomes.
The peroxisomes possess
a β-oxidation pathway
for the degradation of,
for example, very long
chain fatty acids,
also for the oxidation of
bile acid intermediates.
This usually generates
hydrogen peroxide,
which is generated
by a key enzyme
in the pathway by an
acyl-CoA oxidase.
It also generates acyl-CoA
and chain-shortened fatty acids,
which are routed to mitochondria
for further β-oxidation.
Peroxisomes also harbour an
alpha oxidation pathway for
the degradation of
branched-chain fatty acids
such as phytanic acid,
and phytanic acid can be
alpha oxidised into
pristanic acid,
which can then be degraded
by peroxisomal β-oxidation.
However, peroxisomes
also synthesise lipids,
for example, ether
phospholipids.
The key enzymes for
ether phospholipid
synthesis are peroxisomal.
First, the enzymes
which generate
the specific ether bond
do this in peroxisomes,
but the peroxisomes
cooperate with
the endoplasmic reticulum to
complete ether
lipid biosynthesis.
We distinguish two major groups
of peroxisomal disorders.